



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re: Application of  
**THUROW, et al.**

Examiner: Not Yet Known

Art Unit: Not Yet Known

Application No.: **10/632,414**

Filed: **August 1, 2003**

Title: **METHOD FOR PURIFYING  
PREPROINSULIN**

<p align="center"><b>Certificate of Mailing or Transmission</b></p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the address below, or being facsimile transmitted to the USPTO, on the date indicated below.</p> <p>Date of Deposit <u>December 13, 2004</u></p> <p>Printed Name of Person Signing Certificate <u>Jonas Pierre, Sr.</u></p> <p>Signature _____</p>
---

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE  
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop Sequence  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

Barbara E. Kurys, Reg. No. 34,650  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-2965  
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0053 US NP